XML 46 R51.htm IDEA: XBRL DOCUMENT v2.3.0.15
Commitments And Contingencies (Details) (USD $)
9 Months Ended12 Months Ended
Sep. 30, 2011
Dec. 31, 2010
Number of letters of credit outstanding4 
Letters of credit outstanding, total$ 1,800,000 
Retentions and deductibles associated with insurance policies5,000,000 
Stop-loss insurance on a "claims made" basis for expenses, per member per year400,000 
Commitments to invest, venture capital funds8,600,000 
Commitments to invest in other investments800,000 
Commitments to invest in equity method investments104,800,000 
Description of noncontrolling interest

In 2010, the Company sold a noncontrolling interest in its BioDuro Biologics Pte. Ltd. subsidiary. During the 183-day period commencing in December 2016, the minority equity holders have the right to require the Company to purchase their noncontrolling interests at fair value.

 
Minority Owners Put Expiration Period 183
Total gross unrecognized tax benefits29,400,000 
Unrecognized tax benefits, if recognized that would reduce its effective tax rate16,900,000 
Unrecognized tax benefits, decreases resulting from settlement of audits and the expiration of statutes of limitations5,700,000 
Accrued interest with respect to uncertain tax positions4,100,000 
Accrued penalties with respect to uncertain tax positions900,000 
Celtic Pharma Development Services Bermuda Ltd. [Member]
  
Non-revolving line of credit agreement to finance trade payables 18,000,000
Advances to the borrower$ 16,800,000